Antigenix Therapeutics

Antigenix Therapeutics is a preclinical biotech emerging from stealth with a $7 million seed round to advance its proprietary ADC platform. The company's technology centers on a patented antibody that targets a cancer-specific cell surface protein, aiming to deliver potent payloads with precision while sparing healthy tissue. Its initial focus is on developing therapies for cancers resistant to current treatments, with the goal of filing an IND and advancing its first candidates. The company is led by a team with expertise in ADC development, translational medicine, and biotech venture creation.

Proprietary antibody-drug conjugate (ADC) platform built on a patented monoclonal antibody that targets a unique, tumor-specific cell surface protein. The platform utilizes a proprietary stable linker and tailored payloads designed for precise delivery and controlled activation within cancer cells, with the flexibility to support multiple formats including bispecific ADCs and T-cell engagers.

The ADC therapeutic landscape is highly competitive, dominated by large pharmaceutical companies (e.g., AstraZeneca, Daiichi Sankyo, Roche) and numerous biotech innovators. Antigenix must differentiate through superior targeting, novel biology, or improved therapeutic index to capture market share.